Accenture Chief Executive Officer Julie Sweet has been diagnosed with early-stage breast cancer and the treatment is likely to last 12-16 weeks, Moneycontrol has learnt. “I was very recently ...

Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer. With an excellent prognosis and a curable condition, she will undergo surgery and radiation treatment while continuing ...

Good morning. Accenture CEO Julie Sweet announced yesterday that her breast cancer has come back, noting in a memo to staff ...

Today, Accenture plc (NYSE:ACN), a $243 billion market cap technology consulting giant, disclosed an update on the health of Julie Sweet, the company's Chair and Chief Executive Officer.

Plus: All the news and watercooler chat from Fortune. Good morning. Accenture CEO Julie Sweet announced yesterday that her breast cancer has come back, noting in a memo to staff that “the prognosis ...

Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer and the treatment is likely to last 12-16 weeks, according to a Moneycontrol report. However, the CEO will continue to ...

Today, Accenture plc (NYSE:ACN), a $243 billion market cap technology consulting giant, disclosed an update on the health of Julie Sweet, the company's Chair and Chief Executive Officer. In a message ...

Accenture CEO Julie Sweet was praised this week for her openness regarding a breast cancer diagnosis, which also gave rare insight into how executives disclose their life-altering health news. Sweet, ...